Patient info Search Menu

Halls Max strength Sore Throat Relief Original lozenges,Throaties Max strength Sore Throat Relief Original lozenges,Superdrug Extra strength Throat lozenges – Summary of Product Characteristics (SmPC) for healthcare professionals

Updated:
Key facts
Status:
No longer supplied
Medicine strength:
2.5 mg + 1.2 mg
Contains active substances:

Summary of Product Characteristics (SmPC) - Halls Max strength Sore Throat Relief Original lozenges,Throaties Max strength Sore Throat Relief Original lozenges,Superdrug Extra strength Throat lozenges

1 NAME OF THE MEDICINAL PRODUCT

Halls Max Strength Sore Throat Relief Original Lozenges

Throaties Max Strength Sore Throat Relief Original Lozenges

Superdrug Extra Strength Throat Lozenges

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Hexylresorcinol 2.5mg and Benzalkonium Chloride Solution 1.2mg

3 PHARMACEUTICAL FORM

Lozenge

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Symptomatic relief of sore throat, the associated pain and pharyngitis.

4.2 Posology and method of administration

Adults (including the elderly) and children over the age of 12: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 8 lozenges in 24 hours.

Children aged 7 to 12 years: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 4 lozenges in 24 hours. Not to be given to children under 7 years.

4.3 Contraindications

Patients with hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Keep out of reach & sight of children. If symptoms persist, consult your doctor. Contains a total of 2.4g of sucrose and liquid glucose solid per lozenge. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

None

4.6 Pregnancy and lactation

There is a lack of evidence of safety of the product in human pregnancy and in animals, but both hexylresorcinol and benzalkonium chloride have been used widely in lozenges for many years without apparent ill consequence. However, as with all medicines, caution should be exercised during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

None

4.8 Undesirable effects

Isolated cases of hypersensitivity reaction, including rash, urticaria and angioedema, have been reported. There have been isolated reports of tongue soreness.

4.9 Overdose

The oral toxic dose of benzalkonium chloride is between 1 and 3g, symptoms of overdose are unlikely with a product containing such a low level. An overdose of hexylresorcinol may cause minor gastrointestinal irritation. After withdrawal of the product, treatment is symptomatic.

Theoretically symptoms are possible in children if at least 50 lozenges are consumed in a short space of time. In such extreme overdose, related to menthol ingestion, symptoms may include nausea, vomiting diarrhoea, profuse sweating and intense thirst.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic effective for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.

Benzalkonium chloride is a quaternary ammonium compound with antiseptic activity typical of this group

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

There are no preclinical data of any relevance additional to that already included in other sections of the SmPC.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose, liquid glucose, propylene glycol, eucalyptus oil and levomenthol

6.2 Incompatibilities

Benzalkonium chloride is incompatible with other anionic surfactants, citrates, iodides, nitrates, permanganates, salicylates, tartrates and alkalis. Incompatibilities have also been reported with other substances including aluminium, hydrogen peroxide, kaolin and some sulphonamides.

Hexylresorcinol is also incompatible with alkalis and oxidising agents.

6.3 Shelf life

Three years

6.4 Special precautions for storage

Do not store above 30°C

6.5 Nature and contents of container

Blister strips of PVC 250 microns/PVdC 60 gsm/Aluminium 20 microns.

Pack sizes: 8 (1x8), 10 (1x10), 12 (1x12), 16 (2x8), 20 (2x10), 24 (2x12), 30 ( 3x10), 32 (4x8), 36 (3x12) lozenges.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Not applicable

7 MARKETING AUTHORISATION HOLDER

Ernest Jackson & Co Ltd

High Street

Crediton

Devon

EX17 3AP

United Kingdom

8 MARKETING AUTHORISATION NUMBER

PL 00094/0046

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

16/03/2009

10 DATE OF REVISION OF THE TEXT

12/04/2012

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk)

Last revision stated in the text: 12 April 2012

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Halls Max strength Sore Throat Relief Original lozenges,Throaties Max strength Sore Throat Relief Original lozenges,Superdrug Extra strength Throat lozenges

What these facts mean

Active substances? Benzalkonium, Hexylresorcinol
Strength? 2.5 mg + 1.2 mg
Pharmaceutical form? Lozenge
How is it taken? Oromucosal
Is it available?? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)?
  1. R Respiratory system drugs
    1. R02 Throat preparations
      1. R02A Throat preparations
        1. R02AA Antiseptic throat preparations
          1. R02AA20 various antiseptic throat preparations
Marketing authorisation? PL 00094/0046
Codes? BNF 12030300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.2.0 of 16 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.